Loading
Life sciences · Journal article
Cancers · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Lutetium-177 prostate-specific membrane antigen radioligand therapy ([177Lu]Lu-PSMA-RLT) is an effective treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but no validated PSMA-PET/CT-based biomarker currently identifies patients at risk of early treatment failure. The aim of this study was to assess whether semi-quantitative PSMA-PET/CT parameters, in particular the fraction of PSMA-positive tumor volume with high uptake, are associated with early biochemical progression (EBP) and PSA50 response and secondarily with PSA-PFS and OS. Methods: Semiquantitative PSMA-PET parameters comprised reference lesion SUVmax (RL-SUVmax), SUVmean, total PSMA tumor volume (tPSMA-TV), tPSMA-TV above a fixed SUV threshold of 20 (tPSMA-TV20), the percentage of tPSMA-TV20 within tPSMA-TV (tPSMA-TV%), total lesion quotient (TLQ), TLQ20, and rTLQ%. The co-primary endpoints were EBP, defined as PSA progression according to the PCWG3 criteria within 4 months of the start of treatment, and PSA50 response, defined as a reduction in PSA of at least 50% compared with baseline. PSA-PFS (PCWG3-defined PSA progression or death from any cause) and OS were secondary endpoints. Results: 63 patients were retrospectively included (median follow-up, 20.9 months). In univariable analyses, higher baseline tPSMA-TV% was significantly associated with lower odds of EBP (OR per 10% increase, 0.71; 95% CI, 0.57–0.87; p = 0.001) and higher odds of PSA50 response (OR, 1.31; 95% CI, 1.07–1.61; p = 0.009). It was associated with longer PSA-PFS (HR, 0.75; 95% CI, 0.67–0.84; p < 0.001) and longer OS (HR, 0.81; 95% CI, 0.72–0.91; p < 0.001). Exploratory ROC analysis identified a tPSMA-TV% cut-off of 47.54% for EBP (AUC, 0.73 [95% CI, 0.57–0.86]; sensitivity, 0.61; specificity, 0.93), although this threshold requires external validation. In exploratory models including tPSMA-TV and SUVmean, tPSMA-TV% remained associated with PSA-PFS and OS but not with EBP or PSA50 response. Conclusions: Baseline tPSMA-TV% was associated with EBP, PSA50 response, PSA-PFS and OS in mCRPC patients undergoing [177Lu]Lu-PSMA-RLT, and these associations remained after adjustment for baseline PSA and metastatic presentation. tPSMA-TV% is a candidate prognostic imaging biomarker that requires external validation.